Who are ultra-micronized palmitoylethanolamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ultra-micronized-palmitoylethanolamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ultra-micronized palmitoylethanolamide — Competitive Intelligence Brief

ultra-micronized palmitoylethanolamide (ultra-micronized palmitoylethanolamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endocannabinoid-like lipid mediator / PPAR-α agonist. Area: Neurology / Pain Management / Immunology.

marketed Endocannabinoid-like lipid mediator / PPAR-α agonist PPAR-α; mast cell stabilization Neurology / Pain Management / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ultra-micronized palmitoylethanolamide (ultra-micronized palmitoylethanolamide) — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Ultra-micronized palmitoylethanolamide (um-PEA) is an endogenous lipid mediator that modulates inflammatory and neuropathic pain pathways through PPAR-α activation and mast cell stabilization.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ultra-micronized palmitoylethanolamide TARGET	ultra-micronized palmitoylethanolamide	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Endocannabinoid-like lipid mediator / PPAR-α agonist	PPAR-α; mast cell stabilization

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endocannabinoid-like lipid mediator / PPAR-α agonist class)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ultra-micronized palmitoylethanolamide — Competitive Intelligence Brief. https://druglandscape.com/ci/ultra-micronized-palmitoylethanolamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab